CMS approved NTAP reimbursement of up to $2,171 for Ceribell’s Delirium Monitor System in eligible Medicare cases, effective Oct. 1, 2026. The decision could support hospital adoption of the first FDA-cleared EEG-based delirium monitoring platform.